Five-year trial results confirm that bio-printed insulin-producing scaffolds provide a functional cure for Type 1 Diabetes without the need for immunosuppression, potentially transforming the lives of 9 million patients worldwide.
Researchers have announced five-year results from a landmark clinical trial demonstrating that bio-printed pancreatic scaffolds containing insulin-producing cells can achieve insulin independence in patients with Type 1 diabetes—without requiring immunosuppressive drugs. The findings, presented at the American Diabetes Association Scientific Sessions, suggest that a functional cure for Type 1 diabetes may be within reach.
The trial, conducted across 25 medical centers in the United States, Europe, and Japan, followed 280 patients who received the ViaCyte-developed scaffolds. At the five-year mark, 78% of patients remained completely insulin-independent, while an additional 15% required only minimal supplemental insulin.
"These results exceed anything we've seen in diabetes treatment," said Dr. Howard Foyt, Chief Medical Officer at ViaCyte. "We're talking about patients who were injecting insulin multiple times daily for decades, now living without any exogenous insulin for five years and counting."
The breakthrough lies in the scaffold's unique design. The device contains stem cell-derived beta cells—the insulin-producing cells destroyed by the immune system in Type 1 diabetes—encased in a biocompatible membrane. This membrane allows nutrients and insulin to pass through while blocking immune cells, eliminating the need for immunosuppression.
Patients receive the scaffold through a minimally invasive procedure, with the device implanted just beneath the skin of the forearm. The cells begin producing insulin within weeks, and the body's natural feedback mechanisms regulate glucose levels automatically.
"My life has completely changed," said Emma Chen, 28, who was diagnosed with Type 1 diabetes at age 7 and participated in the trial. "No more finger pricks, no more calculating carbs, no more fear of hypoglycemia while I sleep. I can eat what I want, when I want, like everyone else."
The safety profile has been remarkable. Unlike islet cell transplantation, which requires lifelong immunosuppression with its associated risks of infection and cancer, the scaffold approach has shown no serious device-related adverse events over five years.
Researchers have also been encouraged by the durability of the implants. Initial concerns that the encapsulated cells would die or become dysfunctional have not materialized, with the devices continuing to function well beyond projected timelines. Some patients in early cohorts have now exceeded seven years of insulin independence.
The FDA has granted priority review to ViaCyte's approval application, with a decision expected by early 2028. If approved, the treatment could be available to patients within 18 months.
Cost remains a consideration. Current manufacturing costs exceed $150,000 per device, though economies of scale and manufacturing improvements are expected to reduce this significantly. Several insurers have indicated they would cover the procedure, citing potential long-term savings compared to decades of insulin, glucose monitoring supplies, and complication management.
"Type 1 diabetes has been a death sentence for most of human history, then a life sentence of constant management," said Dr. Foyt. "We're now seeing the possibility of a full pardon."
The success has sparked intense interest in applying similar approaches to other autoimmune conditions, including multiple sclerosis, rheumatoid arthritis, and lupus.